TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11676096

Group type: EXPERIMENTAL
Intervention: Synthesized voice (extrovert or introvert)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthesized voice with added personality of the text
Number of subjects: 0
Study: 9389778

Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 200 cm2 area
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 400 cm2 area
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on the largest possible area
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Washing of the application site 30 min after application
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All three application areas
Number of subjects: 16
Study: 7958491

Group type: EXPERIMENTAL
Intervention: Mild hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Euglycemia (control day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Repeat testing after 3 months (experimental day protocol)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: History of unconsciousness due to hypoglycemia
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 26
Study: 2891531

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐noradrenaline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: methoxamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study: 31015068

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vasopressin (AVP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29023319

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 90
Study: 26560512

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 142

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 142
Study: 23941610

Group type: EXPERIMENTAL
Intervention: Virtual advisor walking intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study: 22068326

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions on antibiotic use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pharmacist interventions)
Number of subjects: 0
Study: 19783714

Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg (days 1‐7)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg (days 8‐14)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg (days 1‐7)
Number of subjects: 50
Study: 17108342

Group type: EXPERIMENTAL
Intervention: Target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Subnormal hemoglobin range (10.5 to 11.5 g per deciliter, group 2)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Group 1 (normal range)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Group 2 (subnormal range)
Number of subjects: 603
Study: 12957732

Group type: EXPERIMENTAL
Intervention: Patients with ASD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study: 11103749

Group type: EXPERIMENTAL
Intervention: Commercial grapefruit juice
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Grapefruit segments
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Grapefruit extract
Number of subjects: 4

Group type: COMPARATOR
Intervention: Water
Number of subjects: 4
Study: 8813223

Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atamet
Number of subjects: 30
Study: 1533090

Group type: EXPERIMENTAL
Intervention: 150 mg oral micronized dehydroepiandrosterone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized dehydroepiandrosterone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3925707

Group type: EXPERIMENTAL
Intervention: Aureomycin mouth rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zendium dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zendium dentifrice (pH changed from 5.9 to 6.8)
Number of subjects: 0
Study: 31176622

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Luteinising hormone-releasing hormone agonist (LHRHa) alone
Number of subjects: 65
Study: 30185192

Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs (REP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: REP + coaching
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: REP + coaching + facilitation
Number of subjects: 200

Group type: COMPARATOR
Intervention: REP
Number of subjects: 200
Study: 27258183

Group type: EXPERIMENTAL
Intervention: Parkinson disease patients walking in medication-off condition
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy subjects walking at preferred and slow speeds
Number of subjects: 23
Study: 24762424

Group type: COMPARATOR
Intervention: Warm environment (25.0 ± 0.1 °C, 50.8 ± 1.5% RH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold environment (0.4 ± 1.0 °C, 68.8 ± 7.5% RH)
Number of subjects: 10
Study: 22410606

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (8 weeks of individual exercise education and exercise adherence strategy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 24
Study: 20236661

Group type: EXPERIMENTAL
Intervention: Natalizumab plus interferon beta‐1a
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Interferon beta‐1a alone
Number of subjects: 1171
Study: 19065889

Group type: EXPERIMENTAL
Intervention: Compound Tongfu Granule (CTG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 15839187

Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus glipizide
Number of subjects: 225

Group type: COMPARATOR
Intervention: Glipizide monotherapy
Number of subjects: 225
Study: 12456522

Group type: EXPERIMENTAL
Intervention: Usual care plus the completion of an advance directive
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual psychiatric care (control)
Number of subjects: 156
Study: 11077940

Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous pleural effusions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous ascites
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous pericardial effusions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in confirmed tuberculous pleural effusion patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level cut-off
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid/serum lysozyme ratio cut-off
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation between fluid and serum lysozyme levels in tuberculous effusions
Number of subjects: 42
Study: 8869440

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS), 2 puffs (2 mg puff-1) administered three times a day via a spacer device and face mask
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6702646

Group type: EXPERIMENTAL
Intervention: Nifedipine (N), 20 mg, 3 times daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 14
Study: 31205087

Group type: EXPERIMENTAL
Intervention: Intratracheal instillation of R‐spondin1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of pulmonary R‐spondin1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R‐spondin1 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 0
Study: 29664813

Group type: EXPERIMENTAL
Intervention: Nomograms predicting overall survival (OS)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Nomograms predicting cancer-specific survival (CSS)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Nomograms predicting OS and CSS
Number of subjects: 450
Study: 27401357

Group type: EXPERIMENTAL
Intervention: Optometrists
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 96
Study: 25136077

Group type: EXPERIMENTAL
Intervention: Conventional programming (ventricular tachycardia zone ≥170 beats per minute)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: High-rate programming (ventricular tachycardia zone ≥200 beats per minute)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Delayed programming (60-second delay before therapy ≥170 beats per minute)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Appropriate shocks
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Inappropriate therapy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Appropriate antitachycardia pacing only
Number of subjects: 1500
Study: 23188600

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19481335

Group type: EXPERIMENTAL
Intervention: Daily tamoxifen 20mg continuously (daily group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Daily tamoxifen 20mg continuously (daily group) and Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Number of subjects: 80
Study: 17353504

Group type: EXPERIMENTAL
Intervention: Exenatide LAR 0.8 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exenatide LAR 2.0 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo LAR
Number of subjects: 45
Study: 15911118

Group type: EXPERIMENTAL
Intervention: Coupled bilateral protocol (wrist/finger movements on unimpaired limb with active stimulation on impaired limb)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Unilateral/active stimulation (neuromuscular electromyogram-triggered stimulation on impaired wrist/fingers)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No protocol (control group)
Number of subjects: 26
Study: 11746068

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study: 9436565

Group type: EXPERIMENTAL
Intervention: Dobutamine (3 microg x kg(‐1) x min(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enoximone (200 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 30
Study: 11767429

Group type: EXPERIMENTAL
Intervention: Skin puncture (1 mm deep)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No skin puncture
Number of subjects: 50
Study: 3619195

Group type: EXPERIMENTAL
Intervention: terfenadine 180 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: astemizole
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 2746641

Group type: EXPERIMENTAL
Intervention: Single 50‐mg dose of riboflavin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More frequent dosage of riboflavin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavin as a tracer
Number of subjects: 0
Study: 4349414

Group type: EXPERIMENTAL
Intervention: Sodium amylobarbitone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Benzoctamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Withdrawal from drugs
Number of subjects: 8
Study: 31350629

Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinpro™ XT varnish
Number of subjects: 0
Study: 27651330

Group type: EXPERIMENTAL
Intervention: Extremely Randomized Trees (ERT) classifier
Number of subjects: 49

Group type: COMPARATOR
Intervention: Support Vector Machine (SVM)
Number of subjects: 49
Study: 25947394

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Lipo‐PGE1 (Group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No Lipo‐PGE1 administration (Group B)
Number of subjects: 68
Study: 23092171

Group type: EXPERIMENTAL
Intervention: 0.05% CHX application
Number of subjects: 90

Group type: COMPARATOR
Intervention: No CHX application
Number of subjects: 90
Study: 21602833

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg once daily plus sildenafil 25‐100 mg on demand (Group A)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sildenafil 25‐100 mg on demand (Group B)
Number of subjects: 250
Study: 19183097

Group type: EXPERIMENTAL
Intervention: Eccentric resistance exercise (ECC) program for 12 weeks, n = 10
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonexercise control group (CON), n = 6
Number of subjects: 16
Study: 16766780

Group type: EXPERIMENTAL
Intervention: Black tea (6 gm, caffeine 175 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Green tea (6 gm, caffeine 125 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Caffeine (from black and green tea)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hot water (control)
Number of subjects: 29
Study: 15589006

Group type: EXPERIMENTAL
Intervention: BNP group (n = 93)
Number of subjects: 190
Study: 11511821

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 120 mg daily
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 9028689

Group type: COMPARATOR
Intervention: Diet intervention (n = 35)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Diet and exercise intervention (n = 67)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Exercise intervention (n = 54)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 219
Study: 8330498

Group type: EXPERIMENTAL
Intervention: 3 min alcoholic disinfectant (1 min prior handwashing)
Number of subjects: 17708

Group type: EXPERIMENTAL
Intervention: 1 min chlorhexidine detergent (Hibiscrub), 2 min 0.5% chlorhexidine in 70% isopropanol (Hibisol)
Number of subjects: 17708

Group type: COMPARATOR
Intervention: 5 min standard procedure
Number of subjects: 17708
Study: 3088275

Group type: EXPERIMENTAL
Intervention: 0.1 ml of 1% lidocaine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.25 ml of 1% lidocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0 ml of lidocaine (control)
Number of subjects: 8
Study: 29575803

Group type: EXPERIMENTAL
Intervention: TCZ monotherapy
Number of subjects: 296

Group type: COMPARATOR
Intervention: TCZ plus MTX
Number of subjects: 296
Study: 27634376

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Number of subjects: 9
Study: 24118531

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISP) and adenosine triphosphate (ATP) co-administered before and after circumferential pulmonary vein isolation (CPVI)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Various pacing maneuvers with ISP+ATP
Number of subjects: 109
Study: 23253702

Group type: EXPERIMENTAL
Intervention: Statins (mainly Simvastatin 20 mg and Atorvastatin 10 mg)
Number of subjects: 16860

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 16860

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 16860

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 16860
Study: 20855671

Group type: EXPERIMENTAL
Intervention: Esomeprazole as single modality in patients with negative HPSA
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Esomeprazole alone in patients with positive HPSA
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Triple therapy (Esomeprazole, amoxicillin sodium, and clarithromycin) in patients with positive HPSA
Number of subjects: 212
Study: 19126850

Group type: EXPERIMENTAL
Intervention: Auditory Stroop task performance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Obstacle avoidance task performance
Number of subjects: 24
Study: 16884979

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5% to 1.0%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (fentanyl 30 microg/kg with propofol 2-8 mg/kg/h)
Number of subjects: 23
Study: 12496309

Group type: EXPERIMENTAL
Intervention: Psychoeducative group program (15 sessions, 2 hours each)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (traditional support groups)
Number of subjects: 158
Study: 10975425

Group type: EXPERIMENTAL
Intervention: Seeing-and-discriminating pretraining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seeing pretraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pretraining)
Number of subjects: 0
Study: 9287446

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both Interventions (Imagery and Support)
Number of subjects: 47
Study: 8285824

Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 682

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 682
Study: 3320928

Group type: EXPERIMENTAL
Intervention: Cefixime, 8 mg/kg daily for 10 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amoxicillin, 40 mg/kg/day in three divided doses for 10 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 120
Study: 30853490

Group type: EXPERIMENTAL
Intervention: l-Carnitine (L-Car)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alloisoleucine (Allo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCAAs and BCKAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restricted diet without L-Car
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricted diet with L-Car
Number of subjects: 0
Study: 28127808

Group type: EXPERIMENTAL
Intervention: Therapist BI + EUC-B
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Computer BI + EUC-B
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: EUC-ED + EUC-B
Number of subjects: 780

Group type: COMPARATOR
Intervention: Therapist BI
Number of subjects: 780

Group type: COMPARATOR
Intervention: Computer BI
Number of subjects: 780
Study: 25152325

Group type: EXPERIMENTAL
Intervention: MenACWY-TT at 12-15 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MenACWY-TT + DTaP at 15-18 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HibMenCY-TT at 12-15 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: DTaP only at 15-18 months (Control)
Number of subjects: 100
Study: 22589422

Group type: EXPERIMENTAL
Intervention: NRT + MI
Number of subjects: 430

Group type: COMPARATOR
Intervention: NRT + Brief Advice
Number of subjects: 430
Study: 20888580

Group type: EXPERIMENTAL
Intervention: Ghrelin (50 μg)
Number of subjects: 14
Study: 18222449

Group type: EXPERIMENTAL
Intervention: Midcycle pericoital vaginal applications of a mixture of Egyptian bee honey and royal jelly (H/RJ)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard intrauterine insemination (IUI) procedure
Number of subjects: 99
Study: 16936417

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) - 2-5 microg/kg subcutaneous injection once daily for 10 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) - conventional drug therapy plus BMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 39
Study: 12968843

Group type: EXPERIMENTAL
Intervention: Icodextrin during the 12-hour long dwell for 6 weeks
Number of subjects: 18
Study: 10720011

Group type: EXPERIMENTAL
Intervention: Diuretic administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8707483

Group type: EXPERIMENTAL
Intervention: Daily massages for one month
Number of subjects: 29
Study: 1514711

Group type: EXPERIMENTAL
Intervention: captopril 25-50 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: nifedipine SR 20-40 mg twice daily
Number of subjects: 12
Study: 6096193

Group type: EXPERIMENTAL
Intervention: High fibre, low fat and low sodium diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study: 31517848

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang (BHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30200162

Group type: EXPERIMENTAL
Intervention: Adjunct intermittent pneumatic compression with pharmacologic thromboprophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacologic thromboprophylaxis alone
Number of subjects: 0
Study: 27290978

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 72

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 24383508

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion throughout (CC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Late carbohydrate ingestion (PC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No carbohydrate ingestion (PP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Early carbohydrate ingestion (CP)
Number of subjects: 8
Study: 22401984

Group type: EXPERIMENTAL
Intervention: Hard insole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft insole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barefoot condition (Control)
Number of subjects: 0
Study: 20851295

Group type: EXPERIMENTAL
Intervention: Folate (5 mg) plus vitamin B12 (500 μg) supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17545906

Group type: EXPERIMENTAL
Intervention: CT scanning and passive rotation
Number of subjects: 20